Medrobotics

ZeptoMetrix Corporation, located in Franklin, MA, specializes in providing a wide array of analytical reference materials and diagnostic solutions across various sectors including pharmaceuticals, environmental testing, and consumer safety. Their diverse product offerings encompass everything from molecular controls and quality controls to organometallic standards and proficiency testing services. With a commitment to delivering high-quality products, ZeptoMetrix supports laboratories and organizations in achieving reliable and accurate testing outcomes. Their extensive catalog includes analytical materials for microbiology, physical chemistry, and toxicology, aimed at enhancing the efficiency and precision of laboratory processes. Generated from the website

AutoGen is a leading provider of fully automated workflows for the isolation of nucleic acids, serving research and clinical laboratories across the United States and internationally. The company is committed to delivering personalized boutique-level service, offering high-quality extraction services, and a range of instruments and consumables tailored to meet diverse laboratory needs. With proven workflows designed to save time, labor, and costs, AutoGen equips labs with advanced technology for DNA and RNA extraction, including specialized platforms and kits. Their expertise ensures clients receive the highest quality nucleic acid for downstream applications, while their responsive customer service distinguishes them in the industry. Generated from the website

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.